Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy
Conditions: Gastric Cancer; Gastroesophageal Cancer Interventions: Drug: KH903 + Paclitaxel; Drug: Placebo + Paclitaxel Sponsor: Chengdu Kanghong Biotech Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Biotechnology | Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Research | Study